TherapeuticsMD (Nasdaq:TXMD) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TXMD Stoklara Genel Bakış

TherapeuticsMD, Inc. Amerika Birleşik Devletleri'nde bir farmasötik telif şirketi olarak faaliyet göstermektedir.

TXMD temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $996K )

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( $19M )

TherapeuticsMD, Inc. Rakipler

Cumberland Pharmaceuticals

NasdaqGS:CPIX

US$17.8m

LiveCare

OTCPK:LVCE

US$15.2m

IntelGenx Technologies

OTCPK:IGXT

US$29.2m

Aytu BioPharma

NasdaqCM:AYTU

US$14.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti TherapeuticsMD
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.65
52 Haftanın En Yüksek Seviyesi	US$3.07
52 Haftanın En Düşük Seviyesi	US$1.43
Beta	1.13
11 Aylık Değişim	-12.47%
3 Aylık Değişim	5.10%
1 Yıllık Değişim	-40.22%
33 Yıllık Değişim	-95.26%
5 Yıllık Değişim	-99.10%
Halka arzdan bu yana değişim	-96.70%

Son Haberler & Güncellemeler

Recent updates

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Jul 06

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Oct 22

TherapeuticsMD: The Long Road To Profitability

Jul 08

TherapeuticsMD drops 3% despite consensus beating Q1 results

May 06

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

Feb 24

TherapeuticsMD: Annovera May Save The Day

Feb 04

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

Jan 29

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Jan 27

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Dec 30

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Dec 09

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook

Nov 25

Therapeutics MD EPS beats by $0.01, beats on revenue

Nov 09

Hissedar Getirileri

	TXMD	US Pharmaceuticals	US Pazar
7D	3.1%	-1.9%	-0.4%
1Y	-40.2%	23.1%	34.1%

Getiri vs. Endüstri: TXMD geçen yıl % 23.1 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: TXMD geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is TXMD's price volatile compared to industry and market?
TXMD volatility
TXMD Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: TXMD son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: TXMD 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	1	Marlan Walker	www.therapeuticsmd.com

TherapeuticsMD, Inc. Amerika Birleşik Devletleri'nde bir farmasötik telif şirketi olarak faaliyet göstermektedir. BocaGreenMD ve vitaMedMD markaları altında satılan IMVEXXY, BIJUVA ve ANNOVERA reçeteli prenatal vitamin ürünlerini ticarileştirmek için Mayne Pharma ile bir lisans anlaşması vardır. Şirket reçeteli farmasötik ürünlerini ve doğum öncesi vitamin ürünlerini toptan dağıtıcılar ve perakende eczane dağıtıcıları aracılığıyla satmaktadır.

TherapeuticsMD, Inc. Temel Bilgiler Özeti

TherapeuticsMD'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TXMD temel i̇stati̇sti̇kler
Piyasa değeri	US$18.91m
Kazançlar(TTM)	-US$4.83m
Gelir(TTM)	US$996.00k

19.1x

P/S Oranı

-3.9x

F/K Oranı

TXMD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TXMD gelir tablosu (TTM)
Gelir	US$996.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$996.00k
Diğer Giderler	US$5.83m
Kazançlar	-US$4.83m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.42
Brüt Marj	100.00%
Net Kâr Marjı	-485.34%
Borç/Özkaynak Oranı	0%

TXMD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TXMD Stoklara Genel Bakış

Ödüller

Risk Analizi

TherapeuticsMD, Inc. Rakipler

NasdaqGS:CPIX

US$17.8m

OTCPK:LVCE

US$15.2m

OTCPK:IGXT

US$29.2m

NasdaqCM:AYTU

US$14.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Recent updates

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD raises $7M in private placement

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Therapeutics MD Q2 Earnings Preview

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD jumps 12% as top investor discloses insider purchase

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD plunges 42% as merger agreement ends

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Consensus forecasts updated

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Consensus forecasts updated

Price target decreased to US$3.75

Co-Founder notifies of intention to sell stock

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Co-Founder notifies of intention to sell stock

Consensus revenue estimates fall by 24%

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought US$579k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought US$725k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

No longer forecast to breakeven

TherapeuticsMD: The Long Road To Profitability

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Co-Founder exercised options and sold US$70k worth of stock

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

TherapeuticsMD drops 3% despite consensus beating Q1 results

Revenue and earnings beat expectations

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

TherapeuticsMD: Annovera May Save The Day